COSCIENS BIOPHARMA INC (CSCI) Forecast, Price Target & Analyst Ratings

NASDAQ:CSCI • CA22112H1010

2.72 USD
-0.36 (-11.69%)
At close: Sep 3, 2025
2.59 USD
-0.13 (-4.78%)
After Hours: 9/3/2025, 8:07:43 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for COSCIENS BIOPHARMA INC (CSCI).

Forecast Snapshot

Consensus Price Target

Price Target
N/A
N/A

Next Earnings Forecast

Earnings Estimate
Release DateNov 10, 2025

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
N/A
Upside
N/A
From current price of $2.72 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CSCI Current Analyst RatingCSCI Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

CSCI Historical Analyst RatingsCSCI Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
CSCI was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CSCI.
In the previous month the buy percentage consensus was at a similar level.
CSCI was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release DateNov 10, 2025

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2022 2023 2024
Revenue
YoY % growth
CSCI revenue by date.CSCI revenue by date.
5.6M
5.66%
7.143M
27.55%
9.587M
34.22%
EBITDA
YoY % growth
CSCI ebitda by date.CSCI ebitda by date.
-15.06M
-76.14%
-3.186M
78.84%
-12.416M
-289.70%
EBIT
YoY % growth
CSCI ebit by date.CSCI ebit by date.
-15.2M
-74.71%
-4.629M
69.55%
-14.023M
-202.94%
Operating Margin
CSCI operating margin by date.CSCI operating margin by date.
-271.43%-64.80%-146.27%
EPS
YoY % growth
CSCI eps by date.CSCI eps by date.
-2.94
51.96%
-11.00
-274.15%
N/A
68.75%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CSCI Yearly Revenue VS EstimatesCSCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CSCI Yearly EPS VS EstimatesCSCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 0 -50 -100 -150 -200

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

COSCIENS BIOPHARMA INC / CSCI Forecast FAQ

What is the next earnings date for CSCI stock?

COSCIENS BIOPHARMA INC (CSCI) will report earnings on 2025-11-10.